Market Closed -
Nasdaq
04:00:00 2024-05-22 pm EDT
|
5-day change
|
1st Jan Change
|
35.7
USD
|
+1.08%
|
|
-0.67%
|
+40.22%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,748
|
3,259
|
1,369
|
1,413
|
2,190
|
-
|
-
|
Enterprise Value (EV)
1 |
2,453
|
2,819
|
809.9
|
976.4
|
1,810
|
1,818
|
1,825
|
P/E ratio
|
-19.7
x
|
-30.4
x
|
-8.7
x
|
-10.1
x
|
-12.3
x
|
-10.9
x
|
-10.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
80.7
x
|
44.7
x
|
29.2
x
|
18
x
|
43
x
|
30.9
x
|
28.4
x
|
EV / Revenue
|
72.1
x
|
38.7
x
|
17.3
x
|
12.4
x
|
35.5
x
|
25.7
x
|
23.7
x
|
EV / EBITDA
|
-55.1
x
|
-28.7
x
|
-5.12
x
|
-6.03
x
|
-9.4
x
|
-9.08
x
|
-9.11
x
|
EV / FCF
|
31
x
|
-21.6
x
|
-5.19
x
|
-7.11
x
|
-9.35
x
|
-10.6
x
|
-10.9
x
|
FCF Yield
|
3.22%
|
-4.63%
|
-19.3%
|
-14.1%
|
-10.7%
|
-9.42%
|
-9.21%
|
Price to Book
|
9.72
x
|
7.12
x
|
2.75
x
|
3.58
x
|
4.24
x
|
4.41
x
|
4.95
x
|
Nbr of stocks (in thousands)
|
44,326
|
51,332
|
54,865
|
55,487
|
61,358
|
-
|
-
|
Reference price
2 |
62.00
|
63.49
|
24.96
|
25.46
|
35.70
|
35.70
|
35.70
|
Announcement Date
|
3/11/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2.934
|
34.03
|
72.83
|
46.83
|
78.59
|
50.98
|
70.78
|
77.18
|
EBITDA
1 |
-
|
-44.54
|
-98.13
|
-158.3
|
-162
|
-192.6
|
-200.3
|
-200.3
|
EBIT
1 |
-
|
-46.3
|
-100.5
|
-161.3
|
-165.5
|
-221.9
|
-250.4
|
-260.6
|
Operating Margin
|
-
|
-136.05%
|
-138.03%
|
-344.37%
|
-210.62%
|
-435.23%
|
-353.82%
|
-337.68%
|
Earnings before Tax (EBT)
1 |
-
|
-45.59
|
-100.2
|
-154.8
|
-147
|
-205.2
|
-252.1
|
-283.8
|
Net income
1 |
-
|
-54.64
|
-100.2
|
-154.8
|
-147
|
-205.7
|
-239.5
|
-261.6
|
Net margin
|
-
|
-160.55%
|
-137.6%
|
-330.6%
|
-186.99%
|
-403.56%
|
-338.39%
|
-338.96%
|
EPS
2 |
-
|
-3.150
|
-2.090
|
-2.870
|
-2.520
|
-2.903
|
-3.266
|
-3.387
|
Free Cash Flow
1 |
-
|
79.03
|
-130.5
|
-155.9
|
-137.3
|
-193.5
|
-171.2
|
-168
|
FCF margin
|
-
|
232.22%
|
-179.24%
|
-332.98%
|
-174.71%
|
-379.62%
|
-241.86%
|
-217.75%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
7/31/20
|
3/11/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
15.28
|
9.622
|
11.51
|
9.551
|
16.14
|
9.466
|
16.51
|
4.728
|
47.88
|
10.29
|
12.55
|
10.74
|
18.62
|
14.43
|
14.46
|
EBITDA
1 |
-33.3
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-18.42
|
-51.44
|
-49.1
|
-64.64
|
-30.54
|
-
|
-
|
EBIT
1 |
-33.99
|
-36.93
|
-40.81
|
-44.88
|
-38.63
|
-45.33
|
-43.38
|
-57.51
|
-19.31
|
-52.91
|
-53.72
|
-58.11
|
-53.13
|
-61.95
|
-63.75
|
Operating Margin
|
-222.55%
|
-383.84%
|
-354.44%
|
-469.92%
|
-239.36%
|
-478.83%
|
-262.72%
|
-1,216.35%
|
-40.33%
|
-514.3%
|
-427.92%
|
-541.28%
|
-285.42%
|
-429.34%
|
-441%
|
Earnings before Tax (EBT)
1 |
-33.9
|
-36.68
|
-40.26
|
-43
|
-34.86
|
-40.93
|
-38.8
|
-52.87
|
-14.37
|
-48.56
|
-49.18
|
-54.95
|
-52.36
|
-65.25
|
-68
|
Net income
1 |
-33.9
|
-36.68
|
-40.26
|
-43
|
-34.86
|
-40.93
|
-38.8
|
-52.87
|
-14.37
|
-48.56
|
-49.62
|
-54.83
|
-51.48
|
-66.17
|
-68
|
Net margin
|
-221.93%
|
-381.25%
|
-349.64%
|
-450.24%
|
-216.03%
|
-432.37%
|
-234.96%
|
-1,118.17%
|
-30.01%
|
-472.02%
|
-395.23%
|
-510.7%
|
-276.56%
|
-458.55%
|
-470.38%
|
EPS
2 |
-0.6700
|
-0.7100
|
-0.7800
|
-0.7900
|
-0.5900
|
-0.7000
|
-0.6700
|
-0.9000
|
-0.2500
|
-0.6900
|
-0.7006
|
-0.7600
|
-0.7128
|
-0.8034
|
-0.8351
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/3/22
|
8/9/22
|
11/3/22
|
2/23/23
|
5/4/23
|
8/3/23
|
11/2/23
|
2/22/24
|
5/2/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
295
|
440
|
559
|
436
|
380
|
373
|
365
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
79
|
-131
|
-156
|
-137
|
-194
|
-171
|
-168
|
ROE (net income / shareholders' equity)
|
-
|
-52.2%
|
-27%
|
-32.6%
|
-33.2%
|
-37.3%
|
-36%
|
-51.5%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-18.3%
|
-25.6%
|
-24.9%
|
-24.3%
|
-32.7%
|
-42.3%
|
Assets
1 |
-
|
-
|
546.5
|
604.5
|
589.4
|
848.4
|
733.6
|
619.2
|
Book Value Per Share
2 |
-
|
6.380
|
8.920
|
9.090
|
7.110
|
8.420
|
8.090
|
7.210
|
Cash Flow per Share
2 |
-
|
5.080
|
-2.690
|
-2.840
|
-1.760
|
0.2600
|
-3.600
|
-2.120
|
Capex
1 |
-
|
9.1
|
1.6
|
2.84
|
34.5
|
7.92
|
7.39
|
6.93
|
Capex / Sales
|
-
|
26.73%
|
2.19%
|
6.06%
|
43.87%
|
15.53%
|
10.44%
|
8.98%
|
Announcement Date
|
7/31/20
|
3/11/21
|
2/24/22
|
2/23/23
|
2/22/24
|
-
|
-
|
-
|
Last Close Price
35.7
USD Average target price
50.8
USD Spread / Average Target +42.30% Consensus |
1st Jan change
|
Capi.
|
---|
| +40.22% | 2.19B | | +64.23% | 62.59B | | -2.31% | 41.18B | | +45.55% | 40.29B | | -8.29% | 27.9B | | +11.97% | 26.21B | | -21.16% | 19.09B | | +7.54% | 13.08B | | +25.72% | 12.26B | | +27.17% | 12.05B |
Other Biotechnology & Medical Research
|